TIM HORTONS ASIA PACIFIC PTE. LTD.

Business Description

TIM HORTONS ASIA PACIFIC PTE. LTD. is registered as a business entity on 30 March 2020 (4.9 years ago) structured as a Private Company Limited By Shares (Local Company) with 5 officer(s) in-charge. The business jurisdiction is overseen by the Accounting and Corporate Regulatory Authority (ACRA), a government agency from Singapore with the given Business Registration Number / Unique Entity Number (UEN) 202010181N. The business official address is located at 8 Cross Street #28-01/07, Manulife Tower, Singapore 48424 with main trading activity as To Hold And To License The Th Apac Intellectual Property To 3rd Parties in the primary industry of 77400: Leasing Of Non-financial Intangible Assets (eg Patents, Trademarks, Brand Names Etc) using Singapore Dollars - SGD as its default trading currency. The business name remains unchanged since inception. The business annual account filing date falls on 31 July and is currently operational with the status of 'Live Company'. The business paid up share capital is USD 35,600,010, with preference share capital of USD 0, and other share capital at USD 0.

In the past 365 days, TIM HORTONS ASIA PACIFIC PTE. LTD. has received a total of Login to view reported payment review(s). 8 were rated Good and Login to view were rated Poor. The latest review was made on 2023-04-24 and it was reported "Good". The aggregated good payment amount is equivalent to USD 5,968, and aggregated poor payment amount is equivalent to USD Login to view. Its current payment rating of "A" suggest a healthy payment culture where settlement with stakeholders is always prioritised. Since the business is currently active, it also signals positive financial standing. The lack of an appointed auditor indicates that the business is small sized as it did not meet the regulatory requirements of revenue or assets exceeding SGD 10 million, or has more than 50 employees in the previous two fiscal years.

TIM HORTONS ASIA PACIFIC PTE. LTD. is not yet a Prompt Payment Initiative Signatory.

Last updated on 30 April 2023